In advanced tumors or in hypoxic regions of tumor stroma, TAMs polarize to type 2 macrophages inhibiting anticancer immunity through the release of factors encouraging recruitment of regulatory T cells as well as production of transforming growth factor β1 (TGF-β) [11]. The gene discussed is TGFB1; the disease is neoplasm.